Study of antibiotics for difficult Gram-negative infections
Part of Infections clinical trials.
This study is looking at how well two strong antibiotics (ceftazidime/avibactam and cefiderocol) work, with or without another drug called fosfomycin, for treating tough Gram-negative infections. It aims to help doctors understand the best way to use these medicines.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have an infection caused by a difficult-to-treat Gram-negative bacterium.
- You are being treated with one of the following: ceftazidime/avibactam alone, cefiderocol alone, or either drug combined with fosfomycin.
- You (or your parent/guardian if you are a child) must agree to sign a consent form.
- If you are a healthy volunteer, you must be 18 or older and have no significant health problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks at how well two antibiotics, ceftazidime-avibactam and fosfomycin, work together to treat infections caused by highly resistant bacteria called CRE. It may help find the best way to use these medicines.
This study looks at new ways to fight antibiotic-resistant bacteria in people with certain common infections. It may help by testing approaches tailored to the specific germs found in your urine, lungs, or deeper infections.
This study tests whether giving antibiotics chosen specifically for your resistant bacteria before a liver transplant can prevent infections better than the usual standard antibiotics. It aims to improve recovery and lower the risk of serious infection after surgery.
This study tests whether combining two antibiotics (ceftazidime and fosfomycin) works better than ceftazidime alone for hospitalized adults with serious bacterial infections. If you have a severe infection thought to be caused by Gram-negative bacteria, this trial may offer a new treatment option.
This study looks at how a certain antibiotic (ceftazidime-avibactam) works in people with blood cancers or stem cell transplants, and how the drug levels affect the bacteria. It aims to find the best dosing to fight infections and reduce resistance.
This trial tests a specific antibiotic combination (ceftazidime-avibactam) in patients with serious infections that are resistant to other antibiotics, while they are in intensive care. The goal is to see how well this treatment works for critically ill patients.
Hear when a new Antimicrobial Resistance (AMR) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.